These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131 [TBL] [Abstract][Full Text] [Related]
7. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742 [TBL] [Abstract][Full Text] [Related]
8. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395 [TBL] [Abstract][Full Text] [Related]
9. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131 [TBL] [Abstract][Full Text] [Related]
10. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. Kushner BH; Kramer K; Modak S; Cheung NK J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563 [TBL] [Abstract][Full Text] [Related]
11. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F J Clin Oncol; 2004 Sep; 22(17):3549-57. PubMed ID: 15337804 [TBL] [Abstract][Full Text] [Related]
12. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906 [TBL] [Abstract][Full Text] [Related]
13. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881 [TBL] [Abstract][Full Text] [Related]
14. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Cheung NK; Kushner BH; Yeh SD; Larson SM Int J Oncol; 1998 Jun; 12(6):1299-306. PubMed ID: 9592190 [TBL] [Abstract][Full Text] [Related]
15. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]